JP2012250989A - Pancreatic lipase inhibitor and production method of the same - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a pancreatic lipase inhibitor capable of effectively suppressing absorption of neutral fat several hours after administration of a therapeutic agent (after eating).SOLUTION: The pancreatic lipase inhibitor comprises an extracted fraction having a molecular weight of 300k or more, which is obtained by subjecting a Pleurotus eryngii fruit body to low-temperature drying at 90°C or lower, followed by preparing the material in a powder form, then extracting with water at 30°C to 40°C to obtain an extract, and fractioning the extract.

Description

  The present invention relates to a pancreatic lipase inhibitor that effectively suppresses absorption of neutral fat after meal and a method for producing the same.

  Fat overdose causes obesity and hyperlipidemia. In addition, it is known that obesity induces insulin resistance and has a high incidence of diabetes, hypertension and arteriosclerosis. Therefore, drugs that suppress the absorption of fat in food not only are effective in preventing or improving obesity and hyperlipidemia, but also prevent the onset of diabetes, hypertension, arteriosclerosis, etc. caused by obesity. It is thought to contribute to improving the quality of life.

  Pancreatic lipase secreted from the pancreas is a digestive enzyme of neutral fat in the intestinal tract, and the neutral fat ingested by the meal is broken down into fatty acids and monoglycerides by the pancreatic lipase and absorbed from the small intestine. Therefore, a composition that suppresses the activity of pancreatic lipase is considered to be effective in preventing or improving hyperlipidemia and obesity by inhibiting fat absorption from the intestinal tract.

  In fact, orlistat, a pancreatic lipase inhibitor that is marketed in Europe and the United States, is known to suppress fat absorption during meals and exhibit anti-obesity and hyperlipidemia-improving effects. However, since there are many reports of side effects such as gastrointestinal disorders and fatty stool, there is a need for a fat absorption inhibitor that has a mild effect and is highly safe even when ingested over a long period of time.

As a highly safe lipase inhibitor, various plant extracts, for example, various spice extracts, yacon extracts, mate leaf extracts, and the like have been disclosed as lipase inhibitors. Specifically, for example, techniques shown in the following (1) to (11) are known.
(1) Japanese Patent Application No. 11-237307 (Patent Document 1)

This publication describes the use of eringi as a therapeutic agent for hyperlipidemia. An extract obtained by extracting eringi dry powder with hot water at 90 ° C. for 2 hours or a dry powder added with lard and cholesterol. By giving rats with fat diet for 3 weeks, the rate of weight gain is significantly suppressed compared to the group given only high fat diet, blood cholesterol, triglycerides, GOT values and GPT values also It is described that it decreases compared to the group given only a high fat diet.
(2) Journal of Japan Society for Food Science and Technology, Volume 53, p612-618, 2006 (Non-Patent Document 1)

In this document, when each rat was given a dry powder of mushrooms and a high-fat diet supplemented with lard and cholesterol for 3 weeks, the rate of weight gain was significantly suppressed compared to the group that received only the high-fat diet. In both cases, it was described that cholesterol in blood was decreased but neutral fat was comparable, and that neutral liver liver was significantly decreased by administration of eringi, oyster mushroom, and bamboo shimeji.
(3) Japanese Patent Application No. 2004-158463 (Patent Document 2)
In this publication, a component having pancreatic lipase inhibitory activity is isolated from polyphenol contained in oolong tea.
(4) Japanese Patent Application No. 2005-114294 (Patent Document 3)

This publication describes that the hot water extract of Nephirama cypress has pancreatic lipase inhibitory activity, and when administered orally with neutral fat to rats, the rise of neutral fat in the blood was suppressed. Yes.
(5) Japanese Patent Application No. 2003-41188 (Patent Document 4)

This publication describes that the extract of Ascofilum nodosum has pancreatic lipase inhibitory activity, and when administered to mice orally with neutral fat, the increase in blood neutral fat was suppressed. .
(6) Japanese Patent Application No. 11-299329 (Patent Document 5)

This publication describes that at least one extract of lemongrass, allspice, cinnamon, and clove has lipase inhibitory activity.
(7) Japanese Patent Application No. 2000-126043 (Patent Document 6)

This publication describes that the hot water extract of yacon has lipase inhibitory activity. (8) Japanese Patent Application No. 2002-327865 (Patent Document 7)

Mate tea extract has lipase inhibitory activity, and when administered orally with neutral fat to rats, the rise in blood neutral fat was suppressed, and when fed with a high fat diet and fed for 4 weeks, It is described that the increase and the increase of blood neutral fat were suppressed.
(9) Int. J. Obes., 1999, No. 23, pp. 98-105 (Non-patent Document 2)

In this document, when dried oolong tea leaves (Thea sinensis L) were given to mice with a high fat diet, weight gain and accumulation of neutral fat in the liver were suppressed compared to the group with only a high fat diet, Extract the dried oolong tea leaves with 10 times the amount of boiling water for 1 hour, then use the concentrated extract to mix triolein (neutral fat), lecithin and taurocholic acid, and sonicate the prepared emulsion. The results of measuring porcine pancreatic lipase inhibitory activity as a substrate have been reported. Further, it is described that when noradrenaline is added to an adipocyte isolated from a rat and an extract is further added, the degradation of neutral fat is further promoted and caffeine is isolated as an active ingredient thereof.
(10) Int. J. Obes., 1999, No. 23, pp. 174-179 (Non-patent Document 3)

This document reports the results of measuring pancreatic lipase inhibitory activity using a mixture of chitin (20%) and chitosan (80%). In addition, when preparing in the same manner using Triton X-100 or gum arabic instead of lecithin as a surfactant in emulsion preparation, no inhibitory activity was observed, and pancreatic lipase inhibition directly inhibited enzyme activity. Instead, it has been suggested to inhibit enzyme-substrate interactions. In addition, when chitin chitosan mixture was given to mice with a high fat diet, weight gain, liver weight increase, neutral fat accumulation in the liver, serum neutral fat, etc. were suppressed compared to the group fed only with a high fat diet. It has been reported.
(11) J. Nutr. Sci. Vitaminol., 2003, No. 49, pages 340-345 (non-patent document 4)

In this report, the result of measuring pancreatic lipase inhibitory activity using citrus pectin is reported. In addition, when corn oil (2.5 ml / kg) and pectin (250 mg / kg) were orally administered to rats, the increase in blood triglycerides after 2 hours was suppressed compared to the control group. Has been. Furthermore, when pectin is added to the emulsion and separated into an oil layer and an aqueous layer, and the amount of pancreatic lipase in each layer is measured, the amount of pancreatic lipase in contact with the oil layer decreases due to the addition of pectin, and pectin interacts with the enzyme and substrate. Has been suggested to inhibit.

Japanese Patent Application No. 11-237307 Japanese Patent Application No. 2004-158463 Japanese Patent Application No. 2005-114294 Japanese Patent Application No. 2003-41188 Japanese Patent Application No. 11-299329 Japanese Patent Application No. 2000-126043 Japanese Patent Application No. 2002-327865

Journal of Japan Society for Food Science and Technology Volume 53, 612-618, 2006 Int. J. Obes., 1999, No. 23, pp. 98-105 Int. J. Obes., 1999, No. 23, pp. 174-179 J. Nutr. Sci. Vitaminol., 2003, No. 49, 340-345

  The therapeutic agent of the above prior art (1) suppresses an increase in the amount of neutral fat in the blood when a large amount of neutral fat is given. In this case, it is related to the suppression of the increase in neutral fat in the blood, and it is unclear whether the increase in neutral fat after meal is suppressed. It is also unclear whether the absorption of neutral fat is suppressed. There is a possibility that consumption of triglycerides is accelerated, there is a possibility that synthesis in the liver is reduced, etc. About an increase in triglycerides after several hours (after meal) when giving a therapeutic agent Is unknown, and the pancreatic lipase inhibitory activity is not clear.

In the above prior art (2), it is unclear whether the neutral fat accumulation is suppressed by suppressing the neutral fat accumulation in the liver, and whether the increase in neutral fat in the blood after meals is also suppressed. It is unknown. In addition, although the conventional technique (9) measures pancreatic lipase inhibitory activity, the enzyme concentration used is not described, and in the conventional technique (10), the enzyme concentration used for measuring pancreatic lipase inhibitory activity is different. Can not be compared. Moreover, since the said prior art (11) uses what was prepared from the rat pancreas as pancreatic lipase in measurement of pancreatic lipase inhibitory activity, it cannot compare. On the other hand, the extracts described in the above prior arts (3) to (8) are all less effective, and some of them are difficult to obtain raw materials, are expensive, or have a taste problem. It is difficult to take continuously on a daily basis.
The present invention solves the above-mentioned problems in conventional therapeutic agents or treatment methods, and

A pancreatic lipase inhibitor capable of effectively suppressing neutral fat absorption after several hours (after a meal) when a therapeutic agent is given, and a method for producing the same.

The invention according to the present invention solves the above-mentioned conventional problems by the constitution shown in claims 1 and 2 , and the feature of the invention according to claim 1 is that the powder is dried at a low temperature of 90 ° C. or lower and then powdered. It is a pancreatic lipase inhibitor consisting of an extracted fraction having a molecular weight of 300 k or more, which is extracted from water obtained at a temperature of 30 ° C. to 40 ° C. and extracted from the resulting extract .

The feature of the invention described in claim 2 is that the raw eringi fruit body is dried at an initial temperature of 60 ° C. or less until the eringi fruiting body is overheated so that moisture does not hang out from the mushroom. , After being dried at a low temperature by raising the temperature to 90 ° C. or lower, the powdered eringi fruit body is extracted with water at a temperature of 30 ° C. to 40 ° C., and the extract having a molecular weight of 300 k or more is extracted from the extract. There is a method for producing a pancreatic lipase inhibitor characterized by fractionating a fraction .

After the low-temperature drying at 90 ° C. or less according to the present invention , water extraction from a powdered eringi fruit body at a temperature of 30 ° C. to 40 ° C. and fractionation from the resulting extract consists of an extract fraction having a molecular weight of 300 k or more. The pancreatic lipase inhibitor can effectively suppress neutral fat absorption after a meal, and can suppress absorption of excess fat when taken at the time of a meal. Therefore, prevention and improvement of hyperlipidemia and obesity, as well as prevention of the onset of diabetes, hypertension and arteriosclerosis caused by obesity can be expected.

Moreover, since the pancreatic lipase inhibitory effect of the above-mentioned Eringi low-temperature extract according to the present invention is not impaired by heat, it can also be exerted by cooking it by adding it to other foods. There is no restriction | limiting in particular as a form of foodstuff, It can use as a raw material of bread, confectionery, and other processed foods including a drink. Furthermore, it can be used as pet food.

  Furthermore, it can be used as an orally administered drug other than food. For example, it can be used in the form of drinks, tablets, capsules, granules, powders, drops and the like.

  Pancreatic lipase inhibitor based on the low temperature extract of eringi according to the present invention contains water-soluble substances such as vitamins and trehalose possessed by eringi, so it can be expected that their pharmacological effects will also work simultaneously. Since the fraction having a molecular weight of 300 k or more in the present extract has a high inhibitory effect on pancreatic lipase, the extract fraction having a molecular weight of 300 k or more can be used for the above food or the like in order to further enhance the effects of the invention. In this case, since only a fraction with high pancreatic lipase inhibitory activity is used, the amount of the extract to be added to each food can be reduced, and the effect on the taste and flavor of each food can be suppressed.

The graph which shows the change of the relative activity with respect to the amount of eringi extracts. The graph which shows the change of relative activity with respect to extraction temperature. The graph which shows the change of the relative activity with respect to heating time. The graph which shows the relative activity in each molecular weight fraction. The graph which shows the change of relative activity by a lecithin etc. The graph which shows the time-dependent change of the amount of triglycerides in plasma. The graph which shows the amount of neutral fat in chylomicron. Graph showing LPL activity. The graph which shows the time-dependent change of the neutral fat in a clinical trial.

  Hereinafter, the present invention will be specifically described together with examples.

  The pancreatic lipase inhibitor of the present invention is mainly composed of a low temperature extract of eringi. In order to prevent hyperlipidemia, obesity, etc., there is a need for an inexpensive and highly safe pancreatic lipase inhibitor that has a mild action and can be taken for a long period of time. In order to obtain such a pancreatic lipase inhibitor, it is conceivable to use a cheap and daily ingested food as a raw material, and one of them is an edible mushroom. Edible mushrooms are taken on a daily basis, so they are safe.

  The pancreatic lipase inhibitor of the present invention uses eringi, which is a kind of edible mushroom, and has a low-temperature extract as a main component, has excellent lipase inhibitory activity, and is present in the blood after meal as shown below. An increase in neutral fat can be effectively suppressed.

  The pancreatic lipase inhibitor comprising the low-temperature extract of eringi of the present invention as a main component can be produced, for example, by powdering eringi fruit bodies dried at a low temperature of 90 ° C. or lower and adding water to extract the water at a low temperature. it can. It can also be produced by water extraction of raw eringi fruit bodies at a low temperature. In the case of this eringi, water may be added to the chopped or crushed material and extracted with water at a low temperature.

According to the experiment, a preferable lipase inhibitory activity was obtained at a low extraction temperature of 30 ° C. to 40 ° C. If the extraction time is short, the extraction amount is small, but it may be 10 minutes or more, and preferably 30 minutes or more.
As long as the fruit body is dried at a low temperature of 60 ° C. or lower, any drying method such as sun drying or vacuum freeze drying may be used.

However, in the case of a drying method involving heating , first, the initial stage of drying is set to 60 ° C. or lower. This is because when the temperature is raised to 70 ° C. or more from the initial stage of the drying process, the eringi fruit body is boiled and water is dripped from the mushroom, resulting in an increase in loss. If it exceeds 90 ° C and reaches 100 ° C, it boils. Therefore, it is preferable to start drying at about 40 ° C. and gradually increase the temperature to about 60 ° C. as the degree of drying progresses. This drying process is completed in about 12 hours. Further, if the drying progresses to some extent, that is, after the drying has progressed to a state where moisture does not come off from the mushroom due to overheating of the ering fruit body, the temperature may be raised to about 90 ° C. On the other hand, if it exceeds 100 ° C., it may cause scorching and is not preferable.

  As shown in the Examples, those extracted at around 30 ° C. have the strongest inhibitory activity, and when the extraction temperature is higher than 30 ° C., the extraction efficiency decreases. Moreover, what was extracted at about 30 degreeC does not deactivate the inhibitory activity, even if it heats for a fixed time in boiling water. This indicates that the pancreatic lipase inhibitor contained in eringi cannot be extracted at high temperatures, and the inhibitor itself extracted at 50 ° C. or less, particularly around 30 ° C., is stable to heat.

  The pancreatic lipase inhibitor of the present invention can be used in the state of the above extract, or the extract can be dried by freeze drying or the like and used as a solid extract.

  The pancreatic lipase inhibitor of the present invention comprising an extract obtained by water extraction of a dry powder of ering fruiting body at low temperature can be used in a therapeutic method for suppressing absorption of neutral fat after meal by administering an effective amount thereof. it can. An effective dose is, for example, about 0.1 to 1000 mg / kg per dose.

  The pancreatic lipase inhibitor of the present invention suppresses postprandial fat absorption. In addition, since enzyme activity inhibition occurs at any time before, after, and between meals, the effect of the pancreatic lipase inhibitor of the present invention can be obtained. For example, the pancreatic lipase inhibitory effect can be expected even when the enzyme activity is suppressed by ingesting the pancreatic lipase inhibitor of the present invention before eating and then food (lipid) is ingested thereafter. The most effective method of taking the pancreatic lipase inhibitor of the present invention is to take it at the same time as eating, and it is more effective to mix it with beverages and processed foods.

Examples of preparation of a pancreatic lipase inhibitor mainly composed of the low-temperature extract of eringi of the present invention, measurement of pancreatic lipase activity using the pancreatic lipase inhibitor, and fat load test are shown below.
[Preparation of pancreatic lipase inhibitor]

Elingi fruiting bodies dried at 60 ° C. overnight were pulverized, extracted with 15 times the amount of water, extracted at room temperature for 4 hours, freeze-dried, and eringi extract (hereinafter referred to as the pancreatic lipase inhibitor according to the present invention). Simply referred to as “Eringi extract”).
[Example 1: Measurement of pancreatic lipase activity]

(1) 4-methylumbelliferyl oleate was added to 250 μl of a solution prepared with 0.1 mM of 13 mM Tris-HCl, 150 mM NaCl, 1.3 mM CaCl 2 (pH 8) solution, and an eringi extract solution was added, and as a control What added 125 microliters of water instead of the eringi extract was prepared, 125 microliters of lipase (Lipase: 0.15 mg / ml) was added to them, and it was made to react at 25 degreeC for 30 minutes.

  Subsequently, 500 μl of 0.1 M sodium citrate (pH 4.2) was added to stop the reaction, fluorescence was measured at 355 nm for Excitation and 460 nm for Emission, and the activity when water was added as a control was defined as 100%. Activity was sought.

  The change in relative activity when the amount of eringi extract is changed is shown in FIG. 1, the change in relative activity when the extraction temperature is changed is shown in FIG. 2, and the change in relative activity when the heating time is changed is shown in FIG. .

In addition, the eringi extract obtained by the preparation of the pancreatic lipase inhibitor is fractionated to a molecular weight of 3K or less, 3 to 30K, 30 to 300K, 300K or more using an ultrafiltration device (PALL product). FIG. 4 shows the result of determining the relative activity of the minute relative activity by the same method as described above.
[Example 2: Measurement of pancreatic lipase activity]

(2) In 0.1 M TES buffer (pH 7) containing 9 ml of 0.1 M NaCl, triolein 80 mg, lecithin 10 mg, and taurocholic acid 5 mg were suspended by sonication to obtain a substrate. To 100 μl of this substrate, 50 μl of lipase (50 μg / ml) and 100 μl of Sample (the above-mentioned Eringi extract solution) or water were added and reacted at 37 ° C. for 30 minutes. The fatty acids were then extracted with 3 ml heptane: chloroform: MeOH (49: 49: 2) and 1 ml copper reagent was added. After vigorous mixing, the mixture was centrifuged (2000 × g, 10 min), and 200 μl of the upper layer was collected. 200 μl of a coloring solution (0.1% Bathcuproine, 0.05% 3-t-butyl-4-hydroxyanisole in chloroform) was added thereto, and the absorbance at a wavelength of 480 nm was measured. Furthermore, instead of lecithin, the same measurement was performed using Triton X-100 or gum arabic. As a control, relative activity was determined with the activity when water was added as 100%.
FIG. 5 shows changes in relative activities of lecithin, Triton X-100, and gum arabic.

  As shown in FIG. 1, eringi extract inhibited pancreatic lipase in a dose-dependent manner (FIG. 1, method (1)). Moreover, as shown in FIG. 2, when extracted at each temperature, the lipase inhibitory activity was recognized by the extract of 30 degreeC and 40 degreeC. In particular, a strong lipase inhibitory activity was observed in the extract at 30 ° C. On the other hand, the lipase inhibitory activity was hardly observed in the extract at 50 ° C. or higher, and it was found that the optimum extraction temperature was around 30 ° C.

  In addition, when the extract at 30 ° C. is heated in boiling water for a certain period of time, its inhibitory activity is not inactivated (FIG. 3), but the pancreatic lipase inhibitor contained in eringi is not extracted at a high temperature of 50 ° C. or higher. The lipase inhibitor itself extracted at a low temperature around 30 ° C. was found to be stable to heat. Furthermore, the lipase inhibitory active substance contained in the eringi extract was found to be in the high molecular range of 300K or more (FIG. 4).

Furthermore, in the method (2), when the inhibitory activity was measured, the difference was found in the inhibitory activity due to the difference in the surfactant for preparing the emulsion, so that the eringi extract does not directly inhibit pancreatic lipase. It was suggested to inhibit the enzyme-substrate interaction. Incidentally, orlistat, which has been conventionally used as a pharmaceutical in Europe and the United States, binds to the active center of the enzyme and directly inhibits it, which is different from the action of eringi extract. In addition, what inhibits by the effect | action similar to an eringi extract includes a chitin chitosan mixture, pectin, etc. Here, extraction of pectin is generally performed under high temperature acidic conditions, and chitin chitosan is insoluble in water. Therefore, it should be noted that it is clear that the pancreatic lipase inhibitor of the present invention extracted with water at a low temperature is different from these.
[Example 3: Fat tolerance test]

  ICR mice (male, 7 weeks old) were acclimated for one week and then subjected to experiments. After fasting for 20 hours, water (2.5 ml / kg) and corn oil (2.5 ml / kg) were orally administered to the control group, and the extract solution (2.5 ml / kg, extract 250 mg / kg) was administered to the administration group. ) And corn oil (2.5 ml / kg) were orally administered. Before administration of corn oil, 1.5 hours, 3 hours, 4.5 hours, and 6 hours after administration, blood was collected from the tail vein and the amount of triglyceride in plasma was measured (Triglyceride-E of Wako Pure Chemicals). -Use test Wako). After providing a recovery period of 1 week, the same test was conducted with the dose changed.

Dietary neutral fat forms a complex with proteins and is transported through the blood as chylomicrons. Therefore, blood was collected after 1.5 hours in the same manner as described above, and chylomicron triglyceride was separated from 1 μl of plasma with Titangel lipoprotein (product of Helena Laboratories), and then Choletricombo TG (Helena Laboratories). Product) and the chylomicron fraction was quantified by densitometry with Scion Image.
Neutral fat in chylomicron is broken down by lipoprotein lipase (LPL).

Therefore, heparin (1 unit / g) was administered to the tail vein 10 minutes before blood collection after fat loading similar to the corn oil administration to ICR mice described above, and blood was collected 1.5 hours after fat loading and 3 hours later.

3 μl of 25 mM SDS (0.2 M Tris-HCl, pH 8.2) was added to 3 μl of the obtained plasma and treated at 26 ° C. for 1 hour. To this was added 100 μl of a substrate solution containing 0.5 μCi 3H-triolein, 0.4 mg / ml triolein, 20 mg / ml BSA, 0.1% Triton X-100, 20% FBS, 0.1 M Tris-HCl (pH 8.6), and 37 ° C. For 1 hour. 1.625 ml of chloroform: heptane: MeOH (1: 1.37: 1.28) and 0.5 ml of 0.1M K2CO3 / H3BO3 (pH 10.5) were added, mixed, and centrifuged at 3000 rpm, 4 ° C. for 20 minutes. The activity was determined by adding 5 ml of ACS2 to 0.5 ml of the supernatant and measuring with a liquid scintillation counter.

The time-dependent change in the amount of neutral fat in plasma is shown in FIG. 6, the amount of neutral fat in chylomicron is shown in FIG. 7, and the LPL activity is shown in FIG. From these results, it was clarified that the suppression of the increase in the amount of neutral fat in plasma by administration of the extract is not the promotion of decomposition after absorption but the effect by the action of suppressing absorption from the intestinal tract.
[Example 4: Clinical trial]

  Age 35 to 59 years old, neutral fat in the range of 110-275 mg / dl, total cholesterol 300 mg / dl or less, fasting blood glucose 125 mg / dl or less, HbA1c 6.4% or less, GOT A clinical study was conducted on 25 patients (20 males and 5 females) who fall under 60IU / l, GPT of 60IU / l or less, and γ-GTP of 105IU / l or less.

  As a high fat diet, a beverage (fat content 40 g, 426 kcal) prepared by adding 25 g of unsalted butter and 18 g of lard to 150 ml of corn soup was prepared. The test food was prepared by adding 5 g of eringi extract.

  Subjects were fasted after 9 pm the night before the test, the first blood was collected the next morning on an empty stomach, and immediately received a control or test beverage. From the start of the test to the end of the test, all but a small amount of water was fasted.

  Blood samples were collected 6 times every hour just before intake of fat-loaded beverages and up to 5 hours after intake, and the amount of triglyceride in the blood was measured by a standard test method. In addition, the area under the curves (AUC) was calculated by the trapezoidal method from the blood concentration from 0 to 5 hours after ingestion based on the fasting value.

  The change in the amount of neutral fat over time is shown in FIG. At 3 and 4 hours after fat loading, the increase in neutral fat was suppressed by the extract administration (t test, p <0.05). Moreover, in the area under the curve, the control was 286.2 ± 25.3 mg · h / dl (mean value ± SE) and the extract administration was 234.4 ± 16.8 mg · h / dl, which were significantly decreased by the extract administration ( t test, p <0.05).

  From these results, it was clarified that the increase in the amount of neutral fat in plasma after meal was significantly suppressed in humans as well as the effect in ICR mice.

Claims (2)

Pancreatic lipase inhibitor comprising an extract fraction having a molecular weight of 300 k or more obtained by subjecting it to low temperature drying at 90 ° C. or lower, followed by water extraction from powdered eringi fruit bodies at a temperature of 30 ° C. to 40 ° C. . The initial temperature of drying the raw eringi fruit body is set to 60 ° C. or less, and after the eringi fruiting body is overheated, the drying proceeds to a state where moisture does not come off from the mushroom, and then the temperature is lowered to 90 ° C. or less. The pancreas is characterized by being dried at a low temperature by raising and then water-extracting from a powdered ering fruiting body at a temperature of 30 ° C. to 40 ° C., and fractionating an extract fraction having a molecular weight of 300 k or more from the extract. A method for producing a lipase inhibitor.

Images